Toronto Dominion Bank Buys 825 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Toronto Dominion Bank raised its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 2.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,528 shares of the biotechnology company’s stock after purchasing an additional 825 shares during the period. Toronto Dominion Bank’s holdings in Axon Enterprise were worth $12,680,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in AXON. ICA Group Wealth Management LLC bought a new position in shares of Axon Enterprise in the 4th quarter valued at about $26,000. Trivant Custom Portfolio Group LLC purchased a new position in Axon Enterprise in the first quarter worth about $31,000. First PREMIER Bank purchased a new position in Axon Enterprise in the first quarter worth about $33,000. Key Financial Inc grew its position in Axon Enterprise by 367.6% in the fourth quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 125 shares in the last quarter. Finally, Blue Bell Private Wealth Management LLC purchased a new position in Axon Enterprise in the first quarter worth about $41,000. Institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

AXON has been the subject of several recent research reports. JPMorgan Chase & Co. lifted their price target on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research report on Thursday, April 11th. Jefferies Financial Group initiated coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price target for the company. Bank of America started coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target for the company. Craig Hallum boosted their target price on Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Finally, William Blair restated an “outperform” rating on shares of Axon Enterprise in a research report on Wednesday, April 24th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $342.54.

Axon Enterprise Trading Down 0.1 %

Shares of Axon Enterprise stock traded down $0.22 on Friday, hitting $310.59. 347,880 shares of the company traded hands, compared to its average volume of 488,656. The stock’s 50 day moving average price is $294.49 and its 200-day moving average price is $291.73. The company has a current ratio of 2.91, a quick ratio of 2.55 and a debt-to-equity ratio of 0.37. Axon Enterprise, Inc. has a 52 week low of $175.37 and a 52 week high of $329.87. The company has a market cap of $23.44 billion, a PE ratio of 90.82, a PEG ratio of 7.06 and a beta of 0.95.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The firm had revenue of $460.74 million during the quarter, compared to the consensus estimate of $441.57 million. During the same quarter in the previous year, the firm posted $0.51 earnings per share. The company’s revenue was up 34.3% on a year-over-year basis. Equities research analysts predict that Axon Enterprise, Inc. will post 2.35 EPS for the current year.

Insider Activity

In related news, Director Julie A. Cullivan sold 478 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total value of $136,727.12. Following the completion of the transaction, the director now owns 5,546 shares of the company’s stock, valued at $1,586,377.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Jeri Williams sold 308 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total value of $95,501.56. Following the completion of the transaction, the director now owns 1,607 shares of the company’s stock, valued at $498,282.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Julie A. Cullivan sold 478 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $286.04, for a total transaction of $136,727.12. Following the completion of the transaction, the director now directly owns 5,546 shares of the company’s stock, valued at approximately $1,586,377.84. The disclosure for this sale can be found here. Over the last quarter, insiders sold 89,447 shares of company stock valued at $27,684,677. Corporate insiders own 6.10% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.